Researchers at Harvard Medical School have developed a new tool that promises to improve the way pathologists see and evaluate a tumor, by providing detailed clues about the cancer.

The Gastrointestinal Research Foundation (GIRF) has launched a new initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines for digestive cancers, with a focus on projects that might have difficulty attracting funds because they are too experimental or are in the initial stages of development.

Rarecyte Inc., a Seattle-based company making products for tissue and cell analysis, reported picking up $22 million in a series F financing round led by Healthquest Capital. Also participating in the round were existing investors 5AM Ventures and Ron Seubert, Rarecyte’s founder and chief technology officer. The company plans to use the funds to expand global sales of its instruments and consumables platform in research clinical markets.